Long term outcomes of transcutaneous non-image guided bleomycin sclerotherapy in orbital/adnexal lymphatic malformations: a protocol-based management in 69 eyes.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
21
03
2020
accepted:
31
03
2021
revised:
09
02
2021
pubmed:
22
4
2021
medline:
15
4
2022
entrez:
21
4
2021
Statut:
ppublish
Résumé
To study the efficacy and the long-term outcomes of treating micro and macrocystic orbital and/or adnexal lymphatic malformations (OA-LM) with protocol-based bleomycin sclerotherapy. A retrospective interventional study of 69 eyes having OA-LM treated with non-image guided transcutaneous or transconjunctival bleomycin sclerotherapy (1IU/ml aqueous solution) between December 2014 and December 2018. Based on clinical regression, the outcomes were classified as excellent, good, fair and poor. The mean age at presentation was 20 ± 16 years (median 16; range 1 month to 70 years). The orbital-palpebral variant was the most common presentation, seen in 29 patients (42%). Microcystic morphology was seen in 34(49%), macrocystic in 22 (32%) and mixed cyst in 13 (19%) patients. Mean units of bleomycin injected per patient were 9 ± 8 IU (median 5.5 IU, range 1-38 IU). Mean number of treatment sessions required were 2 ± 1 (median 2, range 1-6). The response was excellent in 43 (62%), good in 12 (17%), fair in 9 (13%) and poor in 5 (7%) patients. These responses were comparable across the morphological subgroups (p = 0.24, chi-square test). Adverse reactions noted were inflammation in 11 eyes (16%) and peri-ocular pigmentation in 15 (22%). There was a sustained tumour regression over a mean follow-up duration of 3.5 years (median 3; range 1.5-5 years). Seventy-nine percent of eyes with OA-LM showed a good outcome with transcutaneous and/or transconjunctival non-image guided bleomycin sclerotherapy with no serious adverse events. The results were promising over long-term follow-up.
Identifiants
pubmed: 33879854
doi: 10.1038/s41433-021-01527-9
pii: 10.1038/s41433-021-01527-9
pmc: PMC8956730
doi:
Substances chimiques
Sclerosing Solutions
0
Bleomycin
11056-06-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
789-799Informations de copyright
© 2021. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
Références
Nassiri N, Rootman J, Rootman DB, Goldberg RA. Orbital lymphaticovenous malformations: current and future treatments. Surv Ophthalmol. 2015;60:383–405.
doi: 10.1016/j.survophthal.2015.03.001
Pires AM, Reinehr C, Boff F, Nazar FL. Intralesional bleomycin sclerotherapy of lymphangioma: partial response to treatment. Dermatol Surg. 2015;41:175–7.
doi: 10.1097/DSS.0000000000000237
Bothra N, Panda L, Sheth J, Tripathy D. Role of intralesional bleomycin sclerotherapy as the sole or adjunct treatment of superficial ocular adnexal lymphatic malformations. Eye 2018;32:152–5.
doi: 10.1038/eye.2017.154
Hornblass A. The use of YAG-tipped contact laser in removing orbital lymphangiomas. Plast Reconstr Surg. 1989;83:397.
doi: 10.1097/00006534-198902000-00057
Lam SC, Yuen HKL. Medical and sclerosing agents in the treatment of orbital lymphatic malformations: what’s new? Curr Opin Ophthalmol. 2019;30:380–5.
doi: 10.1097/ICU.0000000000000585
Patel SR, Rosenberg JB, Barmettler A. Interventions for orbital lymphangioma. Cochrane Database Syst Rev. 2019;5(5):CD013000.
pubmed: 31094450
Guinto G, Guinto-Nishimura Y. Orbital lymphangiomas. World Neurosurg. 2014;81:708–9.
doi: 10.1016/j.wneu.2013.02.076
Harris GJ. Orbital vascular malformations: a consensus statement on terminology and its clinical implications. Orbital Society. Am J Ophthalmol. 1999;127:453–5.
doi: 10.1016/S0002-9394(99)00048-3
Yetiser S, Karaman K Treatment of lymphangioma of the face with intralesional bleomycin: case discussion and literature review. J Maxillofac Oral Surg. 2011;10:152–4.
Patel KC, Kalantzis G, El-Hindy N, Chang BY. Sclerotherapy for orbital lymphangioma—case series and literature review. Vivo. 2017;31:263–266.
doi: 10.21873/invivo.11055
Woo YJ, Kim CY, Sgrignoli B, Yoon JS. Orbital lymphangioma: characteristics and treatment outcomes of 12 cases. Korean J Ophthalmol. 2017;31:194–201.
doi: 10.3341/kjo.2016.0034
Lally SE. Update on orbital lymphatic malformations. Curr Opin Ophthalmol. 2016;27:413–5.
doi: 10.1097/ICU.0000000000000291
Berthout A, Jacomet PV, Putterman M, Galatoire O, Morax S. Surgical treatment of diffuse adult orbital lymphangioma: two case studies. J Fr Ophtalmol. 2008;31:1006–17.
doi: 10.1016/S0181-5512(08)74748-X
Perkins JA, Manning SC, Tempero RM, Cunningham MJ, Edmonds JL Jr, Hoffer FA, et al. Lymphatic malformations: review of current treatment. Otolaryngol Head Neck Surg. 2010;142:795–803.
doi: 10.1016/j.otohns.2010.02.026
Nehra D, Jacobson L, Barnes P, Mallory B, Albanese CT, Sylvester KG. Doxycycline sclerotherapy as primary treatment of head and neck lymphatic malformations in children. J Pediatr Surg. 2008;43:451e460.
doi: 10.1016/j.jpedsurg.2007.10.009
Smith MC, Zimmerman MB, Burke DK, Bauman NM, Sato Y, Smith RJ. Efficacy and safety of OK-432 immunotherapy of lymphatic malformations. Laryngoscope 2009;119:107–15.
doi: 10.1002/lary.20041
Alomari AI, Karian VE, Lord DJ, Padua HM, Burrows PE. Percutaneous sclerotherapy for lymphatic malformations: a retrospective analysis of patient-evaluated improvement. J Vasc Inter Radio. 2006;17:1639–48.
doi: 10.1097/01.RVI.0000239104.78390.E5
Barnacle AM, Theodorou M, Maling SJ, Abou-Rayyah Y. Sclerotherapy treatment of orbital lymphatic malformations: a large single-centre experience. Br J Ophthalmol. 2016;100:204–8.
doi: 10.1136/bjophthalmol-2015-306657
Cheng J. Doxycycline sclerotherapy in children with head and neck lymphatic malformations. J Pediatr Surg. 2015;50:2143–6.
doi: 10.1016/j.jpedsurg.2015.08.051
Yura J, Hashimoto T, Tsuruga N, Shibata K. Bleomycin treatment for cystic hygroma in children. Nihon Geka Hokan. 1977;46:607–14.
pubmed: 73364
Lee KH, Han SH, Yoon JS. Successful treatment of orbital lymphangioma with intralesional bleomycin and application of continuous negative pressure. Korean J Ophthalmol. 2015;29:70–2.
doi: 10.3341/kjo.2015.29.1.70
Dave TV, Javed Ali M, Jyothi AH. Peri-punctal lymphangioma treated with bleomycin. Ophthalmic Plast Reconstr Surg. 2018;34:e140.
doi: 10.1097/IOP.0000000000000983
Kumar V, Kumar P, Pandey A, Gupta DK, Shukla RC, Sharma SP, et al. Intralesional bleomycin in lymphangioma: an effective and safe non-operative modality of treatment. Cutan Aesthet Surg. 2012;5:133–136.
doi: 10.4103/0974-2077.99456
Dave T, Taneja S, Tiple S, Basu S, Naik MN. Conjunctival retention cysts: outcomes of aspiration and sclerotherapy with sodium tetradecyl sulfate. Ophthalmic Plast Reconstr Surg. 2019;35:165–169.
doi: 10.1097/IOP.0000000000001195
Chaudry G, Guevara CJ, Rialon KL, Kerr C, Mulliken JB, Greene AK, et al. Safety and efficacy of bleomycin sclerotherapy for microcystic lymphatic malformation. Cardiovasc Interv Radio. 2014;37:1476–81.
doi: 10.1007/s00270-014-0932-z
Tanigawa N, Shimomatsuya T, Takahashi K, Inomata Y, Tanaka K, Satomura K, et al. Treatment of cystic hygroma and lymphangioma with the use of bleomycin fat emulsion. Cancer 1987;60:741–749.
doi: 10.1002/1097-0142(19870815)60:4<741::AID-CNCR2820600406>3.0.CO;2-2
Zulfiqar MA, Zaleha AM, Zakaria Z, Amin T. The treatment of neck lymphangioma with intralesional injection of bleomycin. Med J Malays. 1999;54:478–481.
Rozman Z, Thambidorai RR, Zaleha AM, Zakaria Z, Zulfiqar MA. Lymphangioma: is intralesional bleomycin sclerotherapy effective? Biomed Imaging Inter J 2011;7:e18.
Porwal PK, Dubey KP, Morey A, Singh H, Pooja S, Bose A. Bleomycin Sclerotherapy in Lymphangiomas of Head and Neck: Prospective Study of 8 Cases. Indian J Otolaryngol Head Neck Surg. 2018;70:145–8.
doi: 10.1007/s12070-017-1243-x
Hanif AM, Saunders JA, Hawkins CM, Wojno TH, Kim HJ. Use of percutaneous bleomycin sclerotherapy for orbital lymphatic malformations. Orbit 2019;38:30–36.
doi: 10.1080/01676830.2018.1480636
Mizuno S, Ishida A. Selective enhancement of bleomycin cytotoxicity by local anesthetics. Biochem Biophys Res Commun. 1982;105:425–31.
doi: 10.1016/0006-291X(82)91451-6
Da Ros V, Iacobucci M, Puccinelli F, Spelle L, Saliou G. Lymphographic-like technique for the treatment of microcystic lymphatic malformation components of <3 mm. Am J Neuroradiol. 2018;39:350–354.
doi: 10.3174/ajnr.A5449
Harmoush S, Chinnadurai P, El Salek K, Metwalli Z, Herce H, Bhatt A, et al. Multimodality image-guided sclerotherapy of low-flow orbital vascular malformations: report of single-center experience. J Vasc Inter Radio. 2016;27:987–995.
doi: 10.1016/j.jvir.2016.02.036
Hill RH 3rd, Shiels WE 2nd, Foster JA, Czyz CN, Stacey A, Everman KR, et al. Percutaneous drainage and ablation as first line therapy for macrocystic and microcystic orbital lymphatic malformations. Ophthalmic Plast Reconstr Surg. 2012;28:119–25.
doi: 10.1097/IOP.0b013e318242ab0f
Paramasivam S, Fay A, FifiJ, Berenstein A. O-015 image guided bleomycin sclerotherapy for orbital lymphatic malformation. J Neuro Interv Surg. 2014;6:A8–9.
Raichura ND, Alam MS, Noronha VO, Mukherjee B. A prospective study of the role of intralesional bleomycin in orbital lymphangioma. J AAPOS. 2017;21:146–151.
doi: 10.1016/j.jaapos.2017.03.007
MacIntosh PW, Yoon MK, Fay A. Complications of intralesional bleomycin in the treatment of orbital lymphatic malformations. Semin Ophthalmol. 2014;29:450–5.
doi: 10.3109/08820538.2014.959617
Cho AL, Kiang SC, Lodenkamp J, Tritch WTH, Tomihama RT. Fatal lung toxicity after intralesional bleomycin sclerotherapy of a vascular malformation. Cardiovasc Interv Radio. 2020;43:648–651.
doi: 10.1007/s00270-020-02420-w